Coronavirus / COVID

6 months after acute COVID-19 infection, patients had elevated usage of health care services to treat post-COVID conditions.

The booster is designed for immunization against the original wild strain as well as Omicron variant.

Neutralization of BA.4 and BA.5 dropped significantly for individuals who were infected with a previous strain of Omicron, even if they were also vaccinated.

Asymptomatic individuals in low-risk settings do not have to quarantine after COVID-19 exposure, CDC says.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

The findings come from a large Dutch study and demonstrate the symptoms of the virus months after people's acute infections.

This study looks to identify safety, efficacy of the vaccine in the youngest pediatric populations.

The benefits outweigh the possible rebound of symptoms, according to an investigator who studied the antiviral.

The modified spike protein in this next-generation bivalent candidate is part of the companies' strategy to try and provide vaccines with longer and more durable protection against the virus.

Omicron-specific vaccine boosters are coming, but just how necessary are they?

The highest rate of myocarditis or pericarditis after mRNA COVID-19 vaccination occurred among young men ages 18 to 24 after receiving a second dose of the Moderna vaccine.

The model suggests screening unvaccinated students could reduce absences by 80% compared to reactively closing classes with infected students.

Clinicians offer insights on a variety of elements surrounding boosters.

Prior infection is not enough: COVID-19 vaccination reduces the risk of reinfection by 50%.

As the pandemic enters its third year, fatigue and frustration grow, but there is hope for the future.

This Israeli study found 3 and 4 doses of Pfizer-BioNTech bolstered antibody titers in adults 60 and older.

He is experiencing mild symptoms and is going to take Paxlovid.

This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.

A specific immunization marker showed the percentage of children receiving common vaccines fell 5% between 2019 and 2021.

The BA.2 COVID-19 variant maintained the mutations necessary for viral entry, but developed an increased ability to evade neutralization by monoclonal antibodies.

Though all racial and ethnic groups saw declines in life expectancy, the impact was greater among members of minority groups.

In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.

CDC attributes a 15% increase in deaths from antimicrobial-resistant infections in 2020 to impacts of COVID-19 on health and healthcare.